Karim A. Benhadji

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque et al. · New England Journal of Medicine · 2023 · 541 citations · Full text

Medicine, Oncology, Pharmacology +16

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · New England Journal of Medicine · 2023 · 428 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · British Journal of Cancer · 2018 · 274 citations · Full text

Medicine, Oncology, Pharmacology +13

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i> / <i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study

Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro et al. · Cancer Discovery · 2021 · 248 citations · Full text

Medicine, Oncology, Pharmacology +10